Abstract
With its facultative ability to induce various types of infection in its hosts, Toxoplasma gondii remains a fascinating and enigmatic pathogen. As a parasite, despite its primitive unicellular structure, it possesses a highly sophisticated arsenal of invasive and defensive tools. Toxoplasmosis has gained widespread significance as a zoonotic disease capable of inducing severe illnesses in humans and drastic economic losses in the veterinary field. Although around a third of the world’s population is infected with Toxoplasma gondii, immunocompromised people, pregnant women, and neonates are more vulnerable to the most severe forms of the disease. Hence, development of a preventive strategy is urgently needed to combat T. gondii infection in both humans and animals. Successful triggering of host immune responses and development of specific immune responses against the different strains and antigens of T. gondii has encouraged researchers to focus on vaccination as a feasible preventive control strategy against toxoplasmosis. In the last few years, vaccine development against T. gondii infections has seen great advances and achievements being made at the research level and, to a lesser extent, in veterinary applications. Currently, only one live attenuated vaccine is available for reducing abortions and fetal losses in pregnant ewes. Otherwise, researchers have investigated numerous classes of vaccine, including live attenuated, recombinant subunit, and vectored. In this chapter we discuss the most commonly investigated vaccines against toxoplasmosis, recombinant DNA and protein vaccines, with special focus on their methodologies and mechanisms of action.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kravetz JD, Federman DG (2005) Toxoplasmosis in pregnancy. Am J Med 118:212–216
Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol 30:1217–1258
Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363:1965–1976
Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP (2010) Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol 4:190–196
Sullivan WJ Jr, Jeffers V (2012) Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol Rev 36:717–733
Kur J, Holec-Gasior L, Hiszczynska-Sawicka E (2009) Current status of toxoplasmosis vaccine development. Expert Rev Vaccines 6:791–808
Innes EA, Bartley PM, Maley S, Katzer F, Buxton D (2009) Veterinary vaccines against Toxoplasma gondii. Mem Inst Oswaldo Cruz 104:246–251
Rodriguez JB, Szajnman SH (2012) New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin Ther Pat 22:311–333
Paquet C, Yudin MH (2013) Toxoplasmosis in pregnancy: prevention, screening and treatment. J Obstet Gynaecol Can 35:78–81
Dautu G, Munyaka B, Carmen G, Zhang G, Omata Y, Xuenan X, Igarashi M (2007) Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp Parasitol 116:273–282
Döşkaya M, Kalantari-Dehaghi M, Walsh CM, Hiszczyńska-Sawicka E et al (2007) GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine. Vaccine 25:1824–1837
Wang PY, Yuan ZG, Petersen E, Li J et al (2012) Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol 19:1916–1920
Gong P, Huang X, Yu Q, Li Y et al (2013) The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice. Parasite Immunol 35:140–146
Hassan IA, Wang S, Xu L, Yan R, Song X, Li X (2014) DNA vaccination with a gene encoding Toxoplasma gondii deoxyribose phosphate aldolase (TgDPA) induces partial protective immunity against lethal challenge in mice. Parasit Vectors 7:431
Golkar M, Shokrgozar MA, Rafati S, Musset K et al (2007) Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 25:4301–4311
Huang X, Li J, Zhang G, Gong P, Yang J, Zhang X (2012) Toxoplasma gondii: protective immunity against toxoplasmosis with recombinant actin depolymerizing factor protein in BALB/c mice. Exp Parasitol 130:218–222
Zheng B, Lu S, Tong Q, Kong Q, Lou D (2013) The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against toxoplasmosis in mice. Vaccine 31:4578–4584
Wang HL, Li YQ, Yin LT, Meng XL, Guo M et al (2013) Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One 8:8
Flori P, Tardy L, Jacquet A, Bellete B, Hafid J, Raberin H, Tran Manh Sung R (2006) Effect of rSAG-1(P30) immunisation on the circulating and tissue parasites in guinea pigs as determined by quantitative PCR. Parasitol Res 98:511–518
Chuang SC, Ko JC, Chen CP, Du JT, Yang CD (2013) Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors 6:34
Qu D, Han J, Du A (2013) Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re. Exp Parasitol 135:234–239
Yu L, Yamagishi J, Zhang S, Jin C, Aboge GO, Zhang H, Zhang G, Tanaka T, Fujisaki K, Nishikawa Y, Xuan X (2012) Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Parasitol Int 61:481–486
Tanaka S, Kuroda Y, Ihara F, Nishimura M, Hiasa J, Kojima N, Nishikawa Y (2014) Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii. Vaccine 32:1781–1785
Fukasawa M, Shimizu Y, Shikata K, Nakata M, Sakakibara R, Yamamoto N, Hatanaka M, Mizuochi T (1998) Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett 441:353–356
Shimizu Y, Takagi H, Nakayama T, Yamakami K, Tadakuma T, Yokoyama N, Kojima N (2007) Intraperitoneal immunization with oligomannose-coated liposome-entrappedsoluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol 29:229–239
Acknowledgement
The first author has been supported by the Egyptian Ministry of High Education and Scientific Research.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Fereig, R.M., Nishikawa, Y. (2016). Towards a Preventive Strategy for Toxoplasmosis: Current Trends, Challenges, and Future Perspectives for Vaccine Development. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1404. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-3389-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3389-1_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-3388-4
Online ISBN: 978-1-4939-3389-1
eBook Packages: Springer Protocols